Strategic Partners Past Earnings Performance
Past criteria checks 0/6
Strategic Partners has been growing earnings at an average annual rate of 42.7%, while the Biotechs industry saw earnings growing at 10.6% annually. Revenues have been declining at an average rate of 5.1% per year.
Key information
42.7%
Earnings growth rate
49.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -5.1% |
| Return on equity | -71.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Strategic Partners makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -11 | 2 | 0 |
| 31 Mar 24 | 0 | -19 | 7 | 0 |
| 31 Dec 23 | 0 | -26 | 13 | 0 |
| 30 Jun 23 | 0 | -27 | 27 | 0 |
| 31 Mar 23 | 0 | -32 | 34 | 0 |
| 31 Dec 22 | 0 | -38 | 41 | 0 |
| 30 Jun 22 | 0 | -48 | 53 | 0 |
| 31 Mar 22 | 0 | -63 | 68 | 0 |
| 31 Dec 21 | 0 | -78 | 83 | 0 |
| 30 Sep 21 | 12 | -327 | 204 | 131 |
| 30 Jun 21 | 0 | -437 | 226 | 194 |
| 31 Mar 21 | 0 | -535 | 237 | 278 |
| 31 Dec 20 | 0 | -633 | 247 | 361 |
| 30 Sep 20 | 0 | -529 | 177 | 336 |
| 30 Jun 20 | 0 | -425 | 106 | 311 |
| 31 Mar 20 | 0 | -381 | 78 | 298 |
| 31 Dec 19 | 0 | -337 | 51 | 285 |
| 30 Sep 19 | 0 | -312 | 46 | 266 |
| 30 Jun 19 | 0 | -286 | 46 | 242 |
| 31 Mar 19 | 0 | -258 | 41 | 218 |
| 31 Dec 18 | 0 | -230 | 35 | 197 |
| 30 Sep 18 | 0 | -206 | 39 | 170 |
| 30 Jun 18 | 0 | -182 | 41 | 145 |
| 31 Mar 18 | 0 | -154 | 37 | 121 |
| 31 Dec 17 | 0 | -126 | 33 | 98 |
| 30 Sep 17 | 0 | -104 | 23 | 86 |
| 30 Jun 17 | 0 | -82 | 13 | 75 |
| 31 Mar 17 | 0 | -70 | 10 | 65 |
| 31 Dec 16 | 0 | -58 | 8 | 56 |
| 31 Dec 15 | 0 | -53 | 8 | 51 |
Quality Earnings: 1TB0 is currently unprofitable.
Growing Profit Margin: 1TB0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1TB0 is unprofitable, but has reduced losses over the past 5 years at a rate of 42.7% per year.
Accelerating Growth: Unable to compare 1TB0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1TB0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.4%).
Return on Equity
High ROE: 1TB0 has a negative Return on Equity (-70.96%), as it is currently unprofitable.